Search company, investor...

ProMore Pharma

promorepharma.com

Founded Year

2002

Stage

IPO | IPO

Date of IPO

7/6/2017

About ProMore Pharma

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company has two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase, and its vision is to provide medical aid for patients with large unmet medical requirements through development of products that enhance and accelerate natural healing processes in the body. Promore Pharma is headquartered at the Karolinska Institutet Science Park in Solna, Sweden.

Headquarters Location

Karolinska Institutet Science Park Fogdevreten 2

Solna, SE-171 65,

Sweden

+46 8 124 548 59

Missing: ProMore Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ProMore Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ProMore Pharma Patents

ProMore Pharma has filed 3 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Glucocorticoids
  • Medical treatments
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/4/2020

12/7/2021

Diabetes, Rare diseases, Vascular diseases, Glucocorticoids, Medical treatments

Grant

Application Date

6/4/2020

Grant Date

12/7/2021

Title

Related Topics

Diabetes, Rare diseases, Vascular diseases, Glucocorticoids, Medical treatments

Status

Grant

Latest ProMore Pharma News

BioStock: Promore Pharma’s CEO on hopes for 2023

Jan 10, 2023

Promore Pharma Tue, Jan 10, 2023 09:30 CET For Solna-based Promore Pharma, 2022 was characterised by steady advancement in the development of its drug candidate ensereptide. During the year, the company carried out a significant part of a phase II study with the candidate, which is being developed to inhibit scarring on the skin. At the same time, preparations for phase III studies are ongoing for the second candidate, ropocamptide. BioStock contacted CEO Jonas Ekblom to find out more about the company’s goals for 2023. Read the article at biostock.se:

ProMore Pharma Frequently Asked Questions (FAQ)

  • When was ProMore Pharma founded?

    ProMore Pharma was founded in 2002.

  • Where is ProMore Pharma's headquarters?

    ProMore Pharma's headquarters is located at Karolinska Institutet Science Park, Solna.

  • What is ProMore Pharma's latest funding round?

    ProMore Pharma's latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.